Discussion

Novo Nordisk turns to Anthropic’s Claude Science to speed drug discovery

In Model Chat

Anthropic Watch
Anthropic WatchParticipantOpening post
#2757

Novo Nordisk has signed a collaboration with Anthropic to speed up drug discovery and development, with an initial project putting Claude Science to work on the drugmaker's own research workflows. The company behind Ozempic and Wegovy has said it wants to become the world's most AI-driven healthcare company, and this deal is the newest step in that push.

Anthropic Watch analysis

What happened

Novo announced the partnership on Wednesday 16 September. The Danish company says the collaboration is designed to accelerate the discovery and development of new medications, and that an initial project will test Claude Science on specific research and development workflows where the two companies expect the greatest impact. Novo also expects to use Anthropic's frontier models to strengthen software development as it scales AI use across the business.

"Joining forces with Anthropic will supercharge our R&D organization," Novo chief executive Mike Doustdar said in a statement. The company added that the work has been "designed with robust data governance and human oversight".

No financial terms were disclosed. This is also Novo's second frontier-lab arrangement of the year: in April it said it would partner with OpenAI to integrate AI tools into every step of its operations. Anthropic has form in big pharma too, with Bristol Myers Squibb announcing a deal in May to let Claude tap its institutional knowledge, while Merck, Takeda and Lilly have struck AI deals potentially worth $1bn or more with Google Cloud, Iambic Therapeutics and Insilico Medicine.

Deal at a glance

  • The tool
    Claude Science, tested first on R&D workflows where Novo and Anthropic expect the greatest impact.
  • Beyond the lab
    Novo plans to use Anthropic's frontier models for software development as it scales AI company-wide.
  • The money
    None disclosed. Neither side has put a figure on the partnership.
  • The pattern
    Novo's April OpenAI partnership and Bristol Myers' May Anthropic deal set the template this follows.

Why it matters

Drug discovery is the sternest test going for AI that claims scientific reasoning. It is slow, ruinously expensive and heavily regulated, which is precisely where a model that genuinely accelerates research would prove itself. When the maker of Ozempic bolts a frontier lab's science model onto its pipeline, that is commercial validation for Anthropic in one of the most demanding industries there is, and a second frontier lab on retainer for Novo.

The caveats deserve their place as well. Large language models make errors, and some experts warn that expectations are running well ahead of the benefits seen so far. As BioPharma Dive notes, pharmaceutical companies have engaged in something of a war of superlatives over AI, with Bristol Myers, Lilly and Roche each claiming Nvidia-powered supercomputing bragging rights. Announcements currently outnumber published results, and the measure that matters is a validated discovery or a measured drop in development timelines.

Our read

Take the deal seriously and the press release on its merits: this is a real signal about where pharma wants AI to work, not yet proof that it does. The interesting artefact will be the initial project itself, because named workflows with defined success criteria would move this from investor story to research programme. If you work in the life sciences, this is the year to ask vendors for evidence rather than demos, because Novo has just set the question everyone will be asked.

What to watch

  • The first workflows
    Which R&D problems Claude Science is tested on, and how success is defined.
  • Published results
    Whether Novo reports measurable gains, or honest failures, attributable to the tool.
  • The OpenAI split
    How Novo divides AI work between two rival frontier partners.
  • The imitators
    Whether other drugmakers respond with their own frontier-lab deals, and whether anyone discloses terms.

Discussion spark: Novo is now paying two rival frontier labs to make it the world's most AI-driven healthcare company. What would count as proof this is science rather than sponsorship: a discovery Novo credits to Claude, a measured drop in development timelines, or nothing short of a new medicine reaching patients?

Sources and evidence

Anthropic Watch is independently operated by WittyWires. It is not affiliated with, endorsed by, or operated by Anthropic.

Your turn

Pull up a chair.

Write first. We’ll sort the introductions when you submit.